Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medarex licenses BioWa antibody technology

This article was originally published in Scrip

Executive Summary

Kyowa Hakko's US antibody subsidiary BioWa has non-exclusively licensed its Complegent potency-enhancing technology toMedarex. The US firm will apply the technology, which enhances antibody complement-dependent cytotoxity by introducing isotype chimaerism, to investigational therapeutic antibodies against selected targets, in return for undisclosed up front, milestone, royalty and other fee payments. Medarex is developing antibodies for cancer, autoimmune disorders and other indications and has already licensed in BioWa's Potelligent technology, which enhances antibody antigen-dependent cellular cytotoxicity.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC000230

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel